School of Medicine
Showing 51-60 of 77 Results
Maria Grazia Roncarolo
George D. Smith Professor of Stem Cell and Regenerative Medicine and Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)On Leave from 03/01/2023 To 02/29/2024
Current Research and Scholarly InterestsResearch Interests
Immunetolerance: Mechanisms underlying T-cell tolerance, induction of T-cell anergy and regulatory T cells; Immunomodulation: mAbs, proteins and low molecular weight compounds which can modulate T-cell activation; Primary immunodeficiencies: Characterization of molecular and immunological defects; Gene therapy: Gene transduction of hematopoietic cells for gene therapy in primary immunodeficiencies and metabolic diseases; Hematopoiesis: Mechanisms underlying growth and differentiation of hematopoietic stem cells; Transplantation: Immune reconstitution and T-cell tolerance after allogenic stem cell transplantation; Cytokines/Cytokine receptors: Role in regulation of immune and inflammatory responses
Monogenic Autoimmune Disorders
Allogenic Bone Marrow Transplantation
Gene Therapy Clinical Trials
Cell Therapy Clinical Trials
Clinical Trials in Autoimmune Diseases and Organ Transplantation
Clinical Trials in Hemoglobinopathies
Michal Bental Roof
Academic Prog Prof 3, Pediatrics - Cardiology
Current Role at StanfordI joined the Cardiopulmonary Research Program of Drs. Rabinovitch and Bland at Stanford University in 2002, as the Academic and Research Program Officer, and since 2020 assumed my role at the Basic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, directed by Dr. Rabinovitch. I organize the educational activities of the lab, and assist the faculty and fellows with the preparation of grant proposals, IRB, APLAC and Biosafety protocols, manuscripts, and presentations. I served as the Site Coordinator for the Stanford Transplant Procurement Center of the Pulmonary Hypertension Breakthrough Initiative (PHBI), headed by Dr. Rabinovitch,that now evolved into the Stanford Transplant Tissue Bank. In this capacity, I oversee patient recruitment, data collection and reporting, and ensure compliance with university and federal guidelines. I coordinated and prepared the application for an Investigational New Drug (IND) and the pre-IND meeting that preceded that, for Elafin as a therapy for pulmonary arterial hypertension (PAH) to the FDA in August 2017, and with the Study PIs coordinated the Phase 1 clinical trial “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” that followed.
From 2005-2015, I served as the Administrative Coordinator of the Cardiovascular and Pulmonary Science Scholarly Concentration for medical students at Stanford University School of Medicine. This includes facilitating communication of the four co-Directors with the School of Medicine Administration, the medical students, and the faculty mentors. An important component of this role is the coordination of the MED223 course, a medical school course where faculty and fellows present new developments in cardiovascular science in the form of a journal club. From 2013-2018, I was the coordinator for the NIH-NHLBI T32 “Mechanisms and Innovation in Vascular Disease” (PI: RL Dalman), and from 2013 to date for NIH-NHLBI K12 HL120001 “Stanford Career Development Program in ‘Omics’ of Lung Disease”. (PIs: M Rabinovitch, MR Nicolls and MP Snyder). This included recruitment of candidates, oversight of training activities, ensuring compliance with NIH and Stanford policies, and acting as a liaison between the trainees and the Directors to facilitate effective communication.
Prior to joining Stanford, I was Associate Director (Scientific Development Administrator) at the Institute for Medicine and Engineering, directed by Dr. Peter Davies at the University of Pennsylvania. In this role, I was the liaison with federal funding agencies and organized multi-investigator program projects and training grants.
Lisa Goldman Rosas
Assistant Professor (Research) of Epidemiology and Population Health and of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics
BioLisa Goldman Rosas, PhD MPH is an Assistant Professor in the Department of Epidemiology and Population Health and the Department of Medicine, Division of Primary Care and Population Health at Stanford School of Medicine. An epidemiologist by training, Dr. Goldman Rosas’ research focuses on addressing disparities in chronic diseases such as diabetes, heart disease, depression, and cancer among racial/ethnic minority families. This research features rigorous quantitative and qualitative methodologies, participatory qualitative approaches, and shared leadership with patient and community partners. She is passionate about integrating patients, caregivers, community organizations, and other key stakeholders in the research process in order to affect the greatest improvements in health and well-being. As a reflection of this passion, Dr. Goldman Rosas serves as the Faculty Director for the School of Medicine Office of Community Engagement, Co-Director of Community-Engaged Research for the Office of Cancer Health Equity, and Director of the Outreach, Recruitment and Engagement Core for the Alzheimer's Disease Research Center. In these roles, she supports other faculty and patient and community partners to develop sustainable and meaningful partnerships to support transformative research. In addition to research, she teaches at the undergraduate and graduate levels and has a special focus on increasing diversity in biomedical research.
Michael J Rosen, MD, MSCI
Stanford University Endowed Professor for Pediatric IBD and Celiac Disease
BioI am a pediatric gastroenterologist and physician scientist, who has been devoted to inflammatory bowel disease (IBD) research since beginning medical training over 20 years ago. I am also Director of the Stanford Center for Pediatric IBD and Celiac Disease. I have expertise crossing mucosal immunology and epithelial biology, formal training and experience in clinical and translational investigation with human biospecimens, and direct insight regarding the important clinical challenges caring for children with complicated IBD. My translational research program focuses on how the immune system regulates epithelial function in chronic intestinal inflammation as it relates to IBD. My clinical research program has focused on optimization of anti-TNF therapy in pediatric IBD, and in particular acute severe ulcerative colitis (ASUC). My laboratory has demonstrated a protective role for IL33, a cytokine that induces type 2 cytokines from T cells an innate lymphoid cells (ILCs), in acute oxazolone colitis through preservation of epithelial goblet cells and barrier function. In line with this finding, we have also shown in a large prospective patient cohort that mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis (UC) from colon-only Crohn’s disease, and that type 2 gene expression is associated with superior clinical outcome in pediatric UC. We have now developed an organoid-immune cell in vitro culture system to demonstrate the ILC2-dependent mechanism through which IL33 induces goblet cell differentiation in the intestinal epithelium. I led the multicenter study Anti-TNF for Refractory Colitis in Hospitalized Children (ARCH) Study, which aims to establish determinants of anti-TNF response in pediatric ASUC and currently Co-Chair the Crohn's & Colitis Foundations Cohort for Pediatric Translational and Clinical Research in IBD (CAPTURE IBD) and PRO-KIIDS Pediatric IBD clinical research network.